1. Home
  2. WGSWW vs CXH Comparison

WGSWW vs CXH Comparison

Compare WGSWW & CXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WGSWW
  • CXH
  • Stock Information
  • Founded
  • WGSWW 2017
  • CXH 1989
  • Country
  • WGSWW United States
  • CXH United States
  • Employees
  • WGSWW 1000
  • CXH N/A
  • Industry
  • WGSWW Retail: Computer Software & Peripheral Equipment
  • CXH Investment Managers
  • Sector
  • WGSWW Technology
  • CXH Finance
  • Exchange
  • WGSWW Nasdaq
  • CXH Nasdaq
  • Market Cap
  • WGSWW N/A
  • CXH N/A
  • IPO Year
  • WGSWW N/A
  • CXH N/A
  • Fundamental
  • Price
  • WGSWW $0.06
  • CXH $7.71
  • Analyst Decision
  • WGSWW
  • CXH
  • Analyst Count
  • WGSWW 0
  • CXH 0
  • Target Price
  • WGSWW N/A
  • CXH N/A
  • AVG Volume (30 Days)
  • WGSWW 36.6K
  • CXH 25.9K
  • Earning Date
  • WGSWW 02-18-2025
  • CXH 01-01-0001
  • Dividend Yield
  • WGSWW N/A
  • CXH 3.56%
  • EPS Growth
  • WGSWW N/A
  • CXH N/A
  • EPS
  • WGSWW N/A
  • CXH 0.23
  • Revenue
  • WGSWW $305,450,000.00
  • CXH N/A
  • Revenue This Year
  • WGSWW N/A
  • CXH N/A
  • Revenue Next Year
  • WGSWW N/A
  • CXH N/A
  • P/E Ratio
  • WGSWW N/A
  • CXH $33.35
  • Revenue Growth
  • WGSWW 50.79
  • CXH N/A
  • 52 Week Low
  • WGSWW $0.17
  • CXH $6.41
  • 52 Week High
  • WGSWW $0.21
  • CXH $7.74
  • Technical
  • Relative Strength Index (RSI)
  • WGSWW N/A
  • CXH 50.52
  • Support Level
  • WGSWW N/A
  • CXH $7.65
  • Resistance Level
  • WGSWW N/A
  • CXH $7.73
  • Average True Range (ATR)
  • WGSWW 0.00
  • CXH 0.06
  • MACD
  • WGSWW 0.00
  • CXH 0.03
  • Stochastic Oscillator
  • WGSWW 0.00
  • CXH 85.79

About WGSWW GeneDx Holdings Corp.

GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.

Share on Social Networks: